Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 5, 2007, Pages 761-767

  Herman, G A ^a   Stein, P P ^a   Thornberry, N A ^a   Wagner, J A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIPIZIDE; METFORMIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL; DIABETIC PATIENT; DISEASE MODEL; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOGLYCEMIA; MONOTHERAPY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT CHANGE;

ANIMALS; ANTIGENS, CD26; CLINICAL TRIALS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; PROTEASE INHIBITORS; PYRAZINES; TRIAZOLES;

EID: 34247269160     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100167     Document Type: Article

References (41)

1. Drucker, D.J. & Nauck, M.A. GLP-1R agonists (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes. Lancet 368, 1696-1705 (2006).
2. Kieffer, T.J. & Habener, J.F. The glucagon-like peptides. Endocr. Rev. 20, 876-913 (1999).
3. Meier, J.J. & Nauck, M.A. Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. Best Pract. Res. Clin. Endocrinol. Metab. 18, 587-606 (2004).
4. Drucker, D.J. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122, 531-544 (2002).
5. Drucker, D.J. The biology of incretin hormones. Cell Metab. 3, 153-165 (2006).
6. Nauck, M.A. et al. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulindependent) diabetic patients. Diabetologia 36, 741-744 (1993).
7. Nauck, M.A. et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab. 87, 1239-1246 (2002).
8. Mentlein, R., Gallwitz, B. & Schmidt, W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214, 829-835 (1993).
9. Weber, A.E. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem. 47, 4135-4141 (2004).
10. Deacon, C.F., Ahren, B. & Holst, J.J. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin. Investig. Drugs 13, 1091-1102 (2004).
11. Vilsboll, T., Krarup, T., Deacon, C.F., Madsbad, S. & Holst, J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50, 609-613 (2001).
12. Green, B.D., Flatt, P.R. & Bailey, C.J. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab. Vasc. Dis. Res. 3, 159-165 (2006).
13. Marguet, D. et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA 97, 6874-6879 (2000).
14. Conarello, S.L. et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. USA 100, 6825-6830 (2003).
15. Miller, S. & St Onge, E.L. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann. Pharmacother. 40, 1336-1343 (2006).
16. Ahren, B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin. Investig. Drugs 15, 431-442 (2006).
17. Augeri, D.J. et al Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48, 5025-5037 (2005).
18. JANUVIA (sitagliptin). Product Information, Merck & Co. Inc: (Whitehouse Station, NJ, October) (2006).
19. Kim, D. et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2, 4]triazolo[4,3-a]pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48, 141-151 (2005).
20. Lankas, G.R. et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54, 2988-2994 (2005).
21. Reimer, M.K., Holst, J.J. & Ahren, B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur. J. Endocrinol. 146, 717-727 (2002).
22. Pospisilik, J.A. et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocininduced diabetic rats. Diabetes 52, 741-750 (2003).
23. Mu, J. et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic b-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55, 1695-1704 (2006).
24. Herman, G.A. et al. Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin. Pharm. Therap. 78, 675-688 (2005).
25. Bergman, A.J. et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin. Ther. 28, 55-72 (2006).
26. Herman, G.A. et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 91, 4612-4619 (2006).
27. Herman, G.A. et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J. Clin. Pharmacol. 46, 876-886 (2006).
28. Herman, G.A., Bergman, A. & Wagner , J. Sitagliptin a DPP-4 inhibitor: An overview of the pharmacokinetic profile and the propensity for drug-drug interactions (abstract). Diabetologia 49 (Suppl. 1): A795 (2006).
29. Bergman, A. et al. Effect of renal insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a selective dipeptidyl peptidase-IV (DPP-IV) inhibitor (abstract). Clin. Pharm. Therap. 79, P75 (2006).
30. Herman, G.A., Bergman, A., Yi, B. & Kipnes, M. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase 4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr. Med. Res. Opin. 22, 1939-1947 (2006).
31. Mistry, G.C. et al Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J. Clin. Pharmacol. 47, 159-164 (2007).
32. Ruddy, M.K. et al. Sitagliptin, a DPP-4 inhibitor, does not inhibit the pharmacokinetics of the sulfonylurea, glyburide (abstract). Diabetes 55 (Suppl. 1): A715 (2006).
33. Herman, G.A. et al. Effect of MK-0431, dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes (abstract). Diabetes 54, A134 (2005).
34. Scott, R., Wu, M., Sanchez, M. & Stein, P.P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int. J. Clin. Pract. 61, 171-180 (2007).
35. Brazg, R. et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-hour glycemic control and b-cell function in patients with type 2 diabetes. Diabetes Obes. Metab. 15, 186-193 (2007).
36. Aschner, P. et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29, 2632-2637 (2006).
37. Raz, I. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49, 2564-2571 (2006).
38. Charbonnel, B., Karasik, A., Liu, J., Wu, M. & Meininger, G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled on metformin alone. Diabetes Care 29, 2638-2643 (2006).
39. Rosenstock, J., Brazg, R., Andryuk, P.J., Lu, K. & Stein, P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-Blind, placebo-controlled parallel group study. Clin. Ther. 28, 1556-1568 (2006).
40. Nauck, M.A., Meininger, G., Sheng, D., Terranella, L., Stein, P.P. & for the Sitagliptin Study 024 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes. Metab. 9, 194-205 (2007).
41. Inzucchi, S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287, 360-372 (2002).